Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05951049 · ClinicalTrials.gov registry record · Phase 2
A Study of AT-02 in Subjects With Systemic Amyloidosis.
A Phase 2 study of Amyloidosis; Systemic, sponsored by Attralus.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 4
- Study locations
NCT05951049 is a Phase 2 study of Amyloidosis; Systemic that is actively recruiting participants, run by Attralus. The registered enrollment target is 120 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT05951049, a Phase 2 study of Amyloidosis; Systemic, is actively recruiting participants, sponsored by Attralus.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Conditions Studied
Interventions
- DRUG AT02
Study Locations (4)
Kansas
- Kansas City - Kansas City
Ohio
- Cleveland Clinic - Cleveland
Oregon
- OHSU (Oregon Health & Science University) - Portland
Pennsylvania
- Penn Presbyterian Medical Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05951049
The ClinicalTrials.gov registry entry for NCT05951049 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Attralus, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Amyloidosis; Systemic appearing as the primary indexed condition, and to 1 intervention - of which AT02 is the first listed.
NCT05951049 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Kansas, Ohio, Oregon.
Frequently Asked Questions
What is clinical trial NCT05951049 about?
NCT05951049 is a clinical study titled "A Study of AT-02 in Subjects With Systemic Amyloidosis.". This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
What is the current status of trial NCT05951049?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2023-09-21. Estimated completion is 2026-02-28.
What conditions does trial NCT05951049 study?
This clinical trial studies the following conditions: Amyloidosis; Systemic.
What interventions are being tested in trial NCT05951049?
The interventions under investigation include: AT02 (DRUG).
Who is sponsoring clinical trial NCT05951049?
This trial is sponsored by Attralus, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05951049 being conducted?
This trial has 4 study locations across Kansas, Ohio, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis; Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.